The effectiveness of Prostatex Plus in the treatment of patients with chronic abacterial prostatitis cate- gories III B

Maslyukov A.V., Kalinichenko D. A., Koltashev A.Yu., Dumenov V.V.

1) Federal State Budgetary Educational Institution of Higher Education «Omsk State Medical University» of the Ministry of Health of the Russian Federation, Omsk, Russia; 2) City Polyclinic No. 11, Omsk, Russia; 3) Assol Reproductive Health Clinic, Omsk, Russia

Introduction. Chronic prostatitis is a pressing medical and social problem. Despite numerous experimental and clinical studies evaluating the effectiveness of various therapeutic agents, optimal treatment regimens for patients with chronic prostatitis have yet to be developed.
Objective: to study the efficacy and safety of Prostatex Plus in the treatment of chronic abacterial prostatitis category III B in comparison with Prostatilen.
Materials and methods. An open-label, randomized cohort study was conducted involving 60 patients aged 37 to 57 years with chronic abacterial prostatitis, category III B. The main group (n=30) received Prostatex Plus 10 mg rectally once daily at night as part of combination therapy, while the comparison group (n=30) received Prostatilen 3 mg rectally once daily at night as part of combination therapy. Therapy with both drugs was administered for 20 days. Based on the NIH-CPSI, IPSS, and IIEF-5 questionnaires, clinical data, and the results of laboratory and instrumental studies, the efficacy and safety of the drugs were assessed in a comparative aspect for 14 days after treatment.
Results. Patients with chronic abacterial prostatitis of categories III B treated with prostate extract-containing medications experienced a reduction in prostate parameters and swelling, leading to normalization of urinalysis and prostate secretion parameters, stable uroflowmetry and ultrasound data, and a reduction in symptoms and complaints. This, in turn, translates into improved urination quality, a reduction in pain and cardiac erectile dysfunction, and an increased quality of life. Furthermore, a comparative analysis demonstrated the greater efficacy of Prostatex Plus compared to Prostatilen.
Discussion. Currently, there is practically no information about the use of Prostatex Plus in patients with chronic prostatitis. Normalization of indicators of general urinalysis and prostate secretion, improvement of uroflowmetry and ultrasound data, relief of clinical symptoms indicate the high effectiveness of the drug in the treatment of chronic prostatitis.
Conclusions. Prostatex Plus is highly effective in the treatment of chronic abacterial prostatitis of categories III B. The use of Prostatex Plus significantly improves clinical and instrumental parameters.

Keywords

About the Authors

Corresponding author: A.V. Maslyukov– urologist, аssistant of the Department of Surgery and Urology FSBEI HE Omsk State Medical University of the Ministry of Health of Russia, Omsk, Russia e-mail: maslyukov.a@inbox.ru

Similar Articles